AstraZeneca and Other Pharma Firms Expand Research Partnerships
阿斯特捷利康與其他製藥公司擴大研究合作關係
更新於: 2026年9月30日 上午03:50
The pharmaceutical industry is undergoing a profound transformation, moving away from traditional, isolated research models toward a collaborative era of 'systematic innovation.'
製藥產業正經歷一場深刻的轉型，從傳統、孤立的研究模式轉向「系統性創新」的協作時代。
Major players like AstraZeneca are leading this shift, exemplified by their recent $2 billion investment in Summit Therapeutics to advance ivonescimab, a groundbreaking cancer drug.
阿斯特捷利康（AstraZeneca）等大廠正引領這項變革，近期投入20億美元與Summit Therapeutics合作，以推進具有突破性的抗癌藥物ivonescimab的開發，即為一例。
AstraZeneca now utilizes artificial intelligence in over 90% of its small molecule pipeline, a trend mirrored by giants like Eli Lilly and AbbVie.
阿斯特捷利康目前在其90%以上的創新小分子藥物研發管線中運用了人工智慧，禮來（Eli Lilly）與艾伯維（AbbVie）等巨頭也採取了類似的趨勢。
By partnering with agile tech firms, these companies are shifting from a 'trial-and-error' approach to a predictive methodology that dramatically accelerates the path from the laboratory to the patient.
透過與靈活的科技公司合作，這些企業正從「試錯法」轉向預測式方法，大幅加快了從實驗室到病患的進程。
As pharmaceutical leaders pair capital with cutting-edge digital technology, the collaborative model has become the primary vehicle for mitigating development risks and addressing the world's most complex, unmet medical needs in areas ranging from oncology to chronic disease management.
隨著製藥龍頭將資金與尖端數位技術相結合，協作模式已成為降低開發風險，並解決從腫瘤學到慢性病管理等領域中，全球最複雜且未被滿足之醫療需求的主要途徑。
